The Symposium on Scientific and Technological Innovation Base of Private Enterprises in Shanghai and the Awarding Ceremony was successfully held on January 2, 2020. As a representative of sci-tech innovative private enterprises, Fosun Pharma was successfully listed as a candidate and awarded the title of Key Laboratory of Stem Cell Therapy Drugs in Shanghai! This is the first time that the Key Laboratory in Shanghai has been awarded to a private enterprise. Wu Qing, a member of the Standing Committee of Shanghai Municipal Committee and Vice Mayor, attended the symposium and awarded the license to scientific and technological innovation base to private enterprise.

Fosun Pharma, in collaboration with ReNeuron (UK), has jointly developed allogeneic stem cell therapy products for the treatment of blindness caused by post-stroke disability and retinitis pigmentosa in stroke patients and patients with rare retinal diseases causing blindness in huge need of treatment. There is no effective treatment for both indications worldwide. In order to promote industrialization, Fosun Pharma actively established its "Key Laboratory of Stem Cell Therapy Drugs" to fully promote global clinical studies, initiate technology transfer and enable stem cell therapy to benefit patients in China and around the world as soon as possible. Fosun Pharma will take these two stem cell technologies as the starting point and strive to build a sound stem cell technology platform in recent years. By introducing foreign advanced technology and talents, Fosun Pharma will integrate a team with stem cell technology as the core backbone and a comprehensive reserve of outstanding talents in technical links for the laboratory, create a unicorn company in stem cell industry and strive to reach the international leading level!

As a joint venture of Shanghai Fosun Pharmaceutical (Group) Co., Ltd and U.S. Kite Pharma, Fosun Kite Biotechnology Co., Ltd. (hereinafter referred to as "Fosun Kite") was established in April 2017 in Shanghai China. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients.

As a leading medical and health industry group in China, Fosun Pharma has abundant experience in pharmaceutical manufacturing and R&D, and has a number of products under research in the field of cancer treatment. Kite Pharma is a global leader in the research and development of T cell immunotherapy. The establishment of the joint venture will take advantage of the resource advantages of both sides to build a leading T cell immunotherapy industry platform in China and jointly provide safe and effective T cell immunotherapy products for Chinese cancer patients.

Oncolytic virotherapy (OV) is a novel tumor therapy that kills tumors by selectively infecting tumor cells with viruses. Oncolytic virus is a kind of tumor-killing virus with replication ability, which can selectively infect tumor cells and replicate in tumor cells and then kill tumor cells, and stimulate the body to produce a specific anti-tumor immune response. Only a few viruses in nature can naturally cause oncolysis, and most of them require genetic modification to achieve the effects of targeted infection of tumor cells and treatment. As an important part of tumor immunity, it has the following advantages over other tumor immunotherapies:

1) Acting on multiple links of tumor immunity, broad-spectrum anti-cancer effect, effective for recurrent and metastatic tumors;

2) Reliable safety, fewer side effects, and no dose-limiting toxicities observed. At present, a number of drugs worldwide are under phase III clinical trials, and have shown good or even revolutionary therapeutic effects in clinical trials, especially in some cancers with very low survival such as glioma, demonstrating great potential, and even achieving lasting disease remission in some patients, which brings forward a promising way for cancer treatment. At present, Fosun Pharma has initiated the development of oncolytic virus products, which is in the preclinical research stage.